Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Year-end Financial Results on June 15, 2018
11 juin 2018 07h00 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals and SunGen Pharma File ANDA for Extended-Release CNS Stimulant
30 mai 2018 07h30 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Announces Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc., USA NORTHVALE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc (OTCBB:ELTP) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals,...
visiongain Logo 72dpi.jpg
Visiongain Launches New Report on the Generic Drugs Market 2018-2028
21 mai 2018 07h34 HE | Visiongain Ltd
LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Visiongain has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe,...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot Study
30 janv. 2018 08h35 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic
10 janv. 2018 08h00 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies for...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP
02 janv. 2018 12h56 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017
09 nov. 2017 16h59 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Groundbreaking prescription tool helps Canadians compare clinical and cost-effectiveness of drugs
08 nov. 2017 09h43 HE | Reformulary Group
TORONTO, ON--(Marketwired - November 08, 2017) - Today, Reformulary Group, Canada's leading, independent drug plan management company, launched DrugFinder™, a consumer app that allows Canadians to...
Elite Pharmaceuticals, Inc. Logo
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2018 Ended June 30, 2017 and Provides Conference Call Information
09 août 2017 16h39 HE | Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...